BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Rhea-AI Summary

BioXcel Therapeutics (Nasdaq: BTAI) announced that Dr. Vimal Mehta, CEO, will participate in three upcoming virtual healthcare investor conferences. These include the Jefferies Virtual Healthcare Conference on June 2, Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, and BofA Securities Napa Biopharma Conference on June 14. The live webcasts will be accessible on the Company's website and archived for 30 days post-event. BioXcel focuses on utilizing artificial intelligence to develop innovative medicines in neuroscience and immuno-oncology.

NEW HAVEN, Conn., May 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in fireside chats at three upcoming virtual healthcare investor conferences.

Presentation Details:

Event: Jefferies Virtual Healthcare Conference
Date: Wednesday, June 2, 2021
Time: 10:30 AM ET

Event: Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Wednesday, June 9, 2021
Time: 4:40 PM ET

Event: BofA Securities Napa Biopharma Conference
Date: Monday, June 14, 2021
Time: 11:30 AM ET

Live webcasts of the fireside chats will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conferences, the webcasts will be archived on the Company’s website for at least 30 days.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com

Investor Relations:
Mary Coleman
BioXcel Therapeutics, VP of Investment Relations
MColeman@bioxceltherapeutics.com
1.475.238.6837

John Graziano
Solebury Trout
jgraziano@soleburytrout.com
1.646.378.2942

Media:

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com
1.646.378.2967

FAQ

What conferences will BioXcel Therapeutics participate in June 2021?

BioXcel Therapeutics will participate in the Jefferies Virtual Healthcare Conference on June 2, Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, and BofA Securities Napa Biopharma Conference on June 14.

Who will represent BioXcel at the investor conferences?

Dr. Vimal Mehta, Founder and CEO of BioXcel, will represent the company during the investor conferences.

How can I access the webcasts for BioXcel's investor conferences?

The live webcasts can be accessed through the Investors section of BioXcel's website.

What is the focus of BioXcel Therapeutics in drug development?

BioXcel Therapeutics focuses on utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology.

What advanced clinical programs are being developed by BioXcel?

BioXcel's two most advanced clinical programs are BXCL501 for agitation and opioid withdrawal, and BXCL701 for aggressive prostate cancer.